Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: Martin K. Bakht Clear advanced filters

  • The epigenetic mechanisms underlying phenotypic diversity across different metastatic sites in castration-resistant prostate cancer (CRPC) remain to be characterised. Here, multi-omic profiling across metastatic lesions identifies regulatory networks driving tumour lineage programs and potential therapeutic targets.

    • Kei Mizuno
    • Sheng-Yu Ku
    • Himisha Beltran
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-13

  • This review explores the basic biology of prostate-specific membrane antigen (PSMA) and its growing significance in molecular imaging and treatment. It emphasizes the importance of understanding PSMA regulation and heterogeneity for the effective application of PSMA-targeted radioligand therapy.

    • Martin K. Bakht
    • Himisha Beltran
    Reviews
    Nature Reviews Urology
    Volume: 22, P: 26-45

  • The transition of androgen receptor-dependent prostate cancer to a therapy resistant cancer with neuroendocrine phenotype is an important process that remains poorly understood. Here, the authors show that PKCλ/ι-loss promotes epigenetic reprogramming resulting in a TGFβ resistance programme via transcriptional upregulation of translational machinery.

    • Shankha S. Chatterjee
    • Juan F. Linares
    • Maria T. Diaz-Meco
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-23

  • Enhancer of zeste homolog 2 (EZH2) has been implicated as a driver of disease progression and resistance to hormonal therapies. Here, the authors focus on EZH2 in two subtypes of advanced prostate cancer and report how it modulates the bivalent genes thereby leading to forward differentiation after being targeted in neuroendocrine prostate cancer.

    • Varadha Balaji Venkadakrishnan
    • Adam G. Presser
    • Himisha Beltran
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-15

  • The heterogeneity of tumor evolution from AR-positive, adenocarcinoma to AR-negative, neuroendocrine prostate cancer (NEPC) is not fully characterized. Here the authors generate a mouse model to show that Rb1 loss and MYCN overexpression accelerates the progression to AR-negative NEPC and identify emergence of distinct subpopulations of NEPC cells.

    • Nicholas J. Brady
    • Alyssa M. Bagadion
    • David S. Rickman
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-17

  • Lineage plasticity and epigenetic changes underlie prostate development and cancer evolution. A new study shows that basal and luminal prostate cells have distinct metabolic profiles, with a basal-to-luminal shift intensifying pyruvate oxidation. Metabolic changes in turn influence chromatin architecture, lineage reprogramming and treatment sensitivity.

    • Martin K. Bakht
    • Himisha Beltran
    News & Views
    Nature Cell Biology
    Volume: 25, P: 1726-1728